- Home
- LNTH vs HSIC Comparison
LNTH vs HSIC Comparison
Compare LNTH & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNTH | HSIC |
|---|---|---|
| Founded | 1956 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 8.8B |
| IPO Year | 2015 | 1995 |
Fundamental Metrics
Financial Performance| Metric | LNTH | HSIC |
|---|---|---|
| Price | $68.61 | $77.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $78.00 | $76.50 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.70 |
| EPS | 2.39 | ★ 3.17 |
| Revenue | $1,525,933,000.00 | ★ $12,938,000,000.00 |
| Revenue This Year | $0.01 | $5.35 |
| Revenue Next Year | $1.24 | $3.34 |
| P/E Ratio | $27.55 | ★ $24.41 |
| Revenue Growth | 1.95 | ★ 3.51 |
| 52 Week Low | $47.25 | $60.56 |
| 52 Week High | $111.29 | $82.49 |
Technical Indicators
Market Signals| Indicator | LNTH | HSIC |
|---|---|---|
| Relative Strength Index (RSI) | 72.42 | 67.52 |
| Support Level | $64.13 | $76.27 |
| Resistance Level | $67.01 | $77.74 |
| Average True Range (ATR) | 2.27 | 1.31 |
| MACD | 0.42 | 0.04 |
| Stochastic Oscillator | 97.77 | 91.42 |
Price Performance
Historical ComparisonAbout LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.